Gelofusine: A new tool for Erythrosedimentation

Area of Science:

• Hematology
• Transfusion Medicine
• Cellular Therapy

Background:

• Allogeneic hematopoietic stem cell transplantation (HSCT) is crucial for treating hematopoietic diseases.
• ABO incompatibility affects 30-40% of HSCTs, posing a risk of hemolysis.
• Red blood cell (RBC) depletion is standard for preventing hemolysis in ABO-incompatible HSCT.

Purpose of the Study:

• To evaluate Gelofusine, a succinyl gelatin-based colloidal solution, as a novel method for RBC depletion.
• To assess Gelofusine's efficacy as a rapid, manual alternative to existing RBC depletion techniques.
• To determine the impact of Gelofusine on white blood cell (WBC) recovery and RBC depletion in cord blood units.

Main Methods:

• A sedimentation procedure using Gelofusine was applied to 30 cord blood units unsuitable for transplantation.
• The mixture was incubated at room temperature until erythrocyte sedimentation and supernatant collection.
• Leukocyte recovery (WBCs) and erythrocyte depletion (RBCs) were quantified, with statistical analysis using one-way ANOVA.

Main Results:

• Gelofusine achieved 90% ± 5% RBC depletion and 79% ± 12% WBC recovery.
• Sedimentation time significantly influenced WBC recovery (p ≤ .02) but not RBC depletion.
• WBC recovery using Gelofusine (79%) was significantly higher than with Hydroxyethyl Starch (HES) solution (66%).

Conclusions:

• Gelofusine is a viable and effective option for RBC depletion in the context of HSCT.
• The Gelofusine method provides a rapid, manual alternative to automated RBC depletion systems.
• Gelofusine demonstrates superior WBC recovery compared to HES solution, making it a promising tool in transfusion medicine.